PRTA -Prothena Corporation plc
Prothena Corporation plcPRTA
$10.25Name : Prothena Corporation plc
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $551,757,312.00
EPSttm : -5.2
Prothena Corporation plc
$10.25
3.22%$0.32Float Short %
9.53
Margin Of Safety %
Put/Call OI Ratio
1.23
EPS Next Q Diff
0.37
EPS Last/This Y
-2.28
EPS This/Next Y
5.02
Price
10.25
Target Price
18.33
Analyst Recom
2
Performance Q
20.31
Relative Volume
1.09
Beta
-0.08
Ticker: PRTA
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-10-20 | PRTA | 10.37 | 1.31 | 0.26 | 27067 |
| 2025-10-21 | PRTA | 10.22 | 1.31 | 1.64 | 27088 |
| 2025-10-22 | PRTA | 9.89 | 1.30 | 0.00 | 27082 |
| 2025-10-23 | PRTA | 9.73 | 1.29 | 0.15 | 27154 |
| 2025-10-24 | PRTA | 9.81 | 1.28 | 0.00 | 27230 |
| 2025-10-27 | PRTA | 10.34 | 1.28 | 0.01 | 27232 |
| 2025-10-28 | PRTA | 10.53 | 1.29 | 0.25 | 27189 |
| 2025-10-29 | PRTA | 10.66 | 1.24 | 3.11 | 27808 |
| 2025-10-30 | PRTA | 10.48 | 1.24 | 0.00 | 27795 |
| 2025-10-31 | PRTA | 10.74 | 1.24 | 0.00 | 27795 |
| 2025-11-03 | PRTA | 10.54 | 1.24 | 1.17 | 27803 |
| 2025-11-04 | PRTA | 10.27 | 1.24 | 0.08 | 28135 |
| 2025-11-05 | PRTA | 10.28 | 1.22 | 0.03 | 28238 |
| 2025-11-06 | PRTA | 10.09 | 1.21 | 0.17 | 28298 |
| 2025-11-07 | PRTA | 10.59 | 1.21 | 0.34 | 28343 |
| 2025-11-10 | PRTA | 10.54 | 1.21 | 0.05 | 28396 |
| 2025-11-11 | PRTA | 10.48 | 1.20 | 0.71 | 28447 |
| 2025-11-12 | PRTA | 10.85 | 1.20 | 0.52 | 28705 |
| 2025-11-13 | PRTA | 10.17 | 1.20 | 2.53 | 29002 |
| 2025-11-14 | PRTA | 9.95 | 1.21 | 4.22 | 29403 |
| 2025-11-17 | PRTA | 10.24 | 1.23 | 2.77 | 29657 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-10-20 | PRTA | 10.37 | 51.1 | - | -4.59 |
| 2025-10-21 | PRTA | 10.21 | 51.1 | - | -4.59 |
| 2025-10-22 | PRTA | 9.88 | 51.1 | - | -4.59 |
| 2025-10-23 | PRTA | 9.74 | 51.1 | - | -4.59 |
| 2025-10-24 | PRTA | 9.82 | 51.1 | - | -4.59 |
| 2025-10-27 | PRTA | 10.36 | 51.1 | - | -4.59 |
| 2025-10-28 | PRTA | 10.54 | 51.1 | - | -4.59 |
| 2025-10-29 | PRTA | 10.66 | 51.1 | - | -4.59 |
| 2025-10-30 | PRTA | 10.48 | 51.1 | - | -4.59 |
| 2025-10-31 | PRTA | 10.75 | 51.1 | - | -4.59 |
| 2025-11-03 | PRTA | 10.57 | 51.1 | - | -4.59 |
| 2025-11-04 | PRTA | 10.26 | 51.1 | - | -4.59 |
| 2025-11-05 | PRTA | 10.27 | 51.1 | - | -4.59 |
| 2025-11-06 | PRTA | 10.07 | 51.1 | - | -4.59 |
| 2025-11-07 | PRTA | 10.56 | 51.1 | - | -4.59 |
| 2025-11-10 | PRTA | 10.53 | 61.3 | - | -4.59 |
| 2025-11-11 | PRTA | 10.48 | 61.3 | - | -4.55 |
| 2025-11-12 | PRTA | 10.85 | 61.3 | - | -4.55 |
| 2025-11-13 | PRTA | 10.17 | 61.3 | - | -4.55 |
| 2025-11-14 | PRTA | 9.96 | 58.3 | - | -4.55 |
| 2025-11-17 | PRTA | 10.25 | 58.3 | - | -4.55 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-10-20 | PRTA | -36.94 | -24.17 | 8.85 |
| 2025-10-21 | PRTA | -36.94 | -24.17 | 8.85 |
| 2025-10-22 | PRTA | -36.94 | -24.17 | 8.85 |
| 2025-10-23 | PRTA | -36.94 | -24.17 | 8.85 |
| 2025-10-24 | PRTA | -36.94 | -24.17 | 8.85 |
| 2025-10-27 | PRTA | -36.94 | -25.35 | 8.87 |
| 2025-10-28 | PRTA | -36.94 | -25.35 | 8.87 |
| 2025-10-29 | PRTA | -36.94 | -25.35 | 8.87 |
| 2025-10-30 | PRTA | -36.94 | -25.35 | 8.87 |
| 2025-10-31 | PRTA | -36.94 | -25.35 | 8.87 |
| 2025-11-03 | PRTA | -37.72 | -25.71 | 8.87 |
| 2025-11-04 | PRTA | -37.72 | -25.71 | 8.87 |
| 2025-11-05 | PRTA | -37.72 | -25.71 | 8.87 |
| 2025-11-06 | PRTA | -37.72 | -25.71 | 8.87 |
| 2025-11-07 | PRTA | 0.00 | -25.71 | 8.87 |
| 2025-11-10 | PRTA | 0.00 | -27.44 | 8.87 |
| 2025-11-11 | PRTA | 0.00 | -27.44 | 8.87 |
| 2025-11-12 | PRTA | 0.00 | -27.44 | 9.54 |
| 2025-11-13 | PRTA | 0.00 | -27.44 | 9.53 |
| 2025-11-14 | PRTA | 0.00 | -27.44 | 9.53 |
| 2025-11-17 | PRTA | 0.00 | -3.09 | 9.53 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.67
Avg. EPS Est. Current Quarter
-0.45
Avg. EPS Est. Next Quarter
-0.3
Insider Transactions
Institutional Transactions
-3.09
Beta
-0.08
Average Sales Estimate Current Quarter
1
Average Sales Estimate Next Quarter
Fair Value
Quality Score
16
Growth Score
44
Sentiment Score
21
Actual DrawDown %
87.2
Max Drawdown 5-Year %
-94.2
Target Price
18.33
P/E
Forward P/E
15.23
PEG
P/S
46.8
P/B
1.87
P/Free Cash Flow
EPS
-5.21
Average EPS Est. Cur. Y
-4.55
EPS Next Y. (Est.)
0.47
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-2379.59
Relative Volume
1.09
Return on Equity vs Sector %
-122
Return on Equity vs Industry %
-107.1
EPS 1 7Days Diff
EPS 1 30Days Diff
0.04
EBIT Estimation
Prothena Corporation plcSector: Healthcare
Industry: Biotechnology
Employees: 163
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. Its product pipeline include Prasinezumab, an investigational humanized monoclonal antibody which is in phase 2b clinical trial, as well as phase 1 and 2 clinical trials for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in phase 2 clinical trial for potential treatment of transthyretin amyloidosis; BMS-986446, an investigational antibody, which is in phase 2 clinical trial to treat Alzheimer's disease; PRX012, an investigational antibody, which is in phase 1 clinical trial to treat Alzheimer's disease; PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease; and PRX019, an investigational antibody, which is in phase 1 clinical trial for the potential treatment of neurodegenerative diseases. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
stock quote shares PRTA -Prothena Corporation plc Stock Price stock today
news today PRTA -Prothena Corporation plc stock forecast ,stock prediction 2023 2024 2025
marketwatch PRTA -Prothena Corporation plc yahoo finance google finance
stock history PRTA -Prothena Corporation plc invest stock market
stock prices PRTA premarket after hours
ticker PRTA fair value insiders trading